Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework. by Carvalho, Natalie et al.
Carvalho, N; Jit, M; Cox, S; Yoong, J; Hutubessy, RCW (2017)
Capturing Budget Impact Considerations Within Economic Evalu-
ations: A Systematic Review of Economic Evaluations of Rotavirus
Vaccine in Low- and Middle-Income Countries and a Proposed As-
sessment Framework. PharmacoEconomics. ISSN 1170-7690 DOI:
https://doi.org/10.1007/s40273-017-0569-2
Downloaded from: http://researchonline.lshtm.ac.uk/4398462/
DOI: 10.1007/s40273-017-0569-2
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/3.0/
SYSTEMATIC REVIEW
Capturing Budget Impact Considerations Within Economic
Evaluations: A Systematic Review of Economic Evaluations
of Rotavirus Vaccine in Low- and Middle-Income Countries
and a Proposed Assessment Framework
Natalie Carvalho1 • Mark Jit2,3 • Sarah Cox4 • Joanne Yoong5,6 •
Raymond C. W. Hutubessy7
Published online: 13 September 2017
 The Author(s) 2017. This article is an open access publication
Abstract
Background In low- and middle-income countries, budget
impact is an important criterion for funding new inter-
ventions, particularly for large public health investments
such as new vaccines. However, budget impact analyses
remain less frequently conducted and less well researched
than cost-effectiveness analyses.
Objective The objective of this study was to fill the gap in
research on budget impact analyses by assessing (1) the
quality of stand-alone budget impact analyses, and (2) the
feasibility of extending cost-effectiveness analyses to
capture budget impact.
Methods We developed a budget impact analysis checklist
and scoring system for budget impact analyses, which we
then adapted for cost-effectiveness analyses, based on
current International Society for Pharmacoeconomics and
Outcomes Research Task Force recommendations. We
applied both budget impact analysis and cost-effectiveness
analysis checklists and scoring systems to examine the
extent to which existing economic evaluations provide
sufficient evidence about budget impact to enable decision
making. We used rotavirus vaccination as an illustrative
case in which low- and middle-income countries uptake
has been limited despite demonstrated cost effectiveness. A
systematic literature review was conducted to identify
economic evaluations of rotavirus vaccine in low- and
middle-income countries published between January 2000
and February 2017. We critically appraised the quality of
budget impact analyses, and assessed the extension of cost-
effectiveness analyses to provide useful budget impact
information.
Results Six budget impact analyses and 60 cost-effective-
ness analyses were identified. Budget impact analyses
adhered to most International Society for Pharmacoeco-
nomics and Outcomes Research recommendations, with
key exceptions being provision of undiscounted financial
streams for each budget period and model validation. Most
cost-effectiveness analyses could not be extended to pro-
vide useful budget impact information; cost-effectiveness
analyses also rarely presented undiscounted annual costs,
or estimated financial streams during the first years of
programme scale-up.
Conclusions Cost-effectiveness analyses vastly outnumber
budget impact analyses of rotavirus vaccination, despite
both being critical for policy decision making. Straight-
forward changes to the presentation of cost-effectiveness
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analyses results could facilitate their adaptation into budget
impact analyses.
Key Points
Despite their equal importance in aiding decision
makers to allocate limited resources, fewer budget
impact analyses are published in the literature
compared with cost-effectiveness analyses.
Furthermore, published budget impact analyses do
not meet current best-practice recommendations
such as not discounting future costs, providing
annual or budget relevant financial streams of costs,
model validation, and sensitivity and scenario
analyses among others.
The proposed framework through which cost-
effectiveness analyses could be used as a tool to
provide useful budget impact analysis information
could facilitate the uptake and improvement of good-
quality budget impact analyses that would be useful
for decision makers, in particular in low- and
middle-income countries.
1 Introduction
Cost effectiveness is one of several key gateway criteria
that inform new technology adoption decisions. However,
interventions found to be cost effective or very cost
effective are often not implemented [1]. While current
uncertainties surrounding appropriate cost-effectiveness
thresholds may explain some of this [1–3], overall
healthcare budget implications and issues of sustainability
also play an important role [4]. Decision makers require
estimates of the real financial consequences of introducing
a new intervention within a defined budget and budgetary
period rather than relying on anticipated savings in eco-
nomic costs alone [1, 5, 6]. The importance of high-quality
budget impact analyses (BIAs) for accurate budgeting and
resource allocation is increasingly recognised, especially
for severely resource-constrained environments [7, 8].
Many high-income countries require budget impact infor-
mation alongside cost-effectiveness estimates when mak-
ing decisions to adopt new interventions [7, 9, 10]. In low-
and middle-income countries (LMICs), understanding the
short- and long-term impact of intervention adoption on
national budgets is critical for ensuring programme
sustainability [11, 12], especially when international
funding is uncertain or of a temporary nature [13].
Unfortunately, the majority of published economic
evaluations are cost-effectiveness analyses (CEAs), with
very few BIAs, especially focused on LMICs [14]. Budget
impact analyses may be conducted as often but less com-
monly published compared with CEAs for a variety of
reasons, including secrecy on behalf of industry not
wanting to disclose tender prices, or journal editors
believing BIAs to be more of an administrative or financial
task rather than research. Another possible explanation is
that appropriate methodology for a BIA remains less well
researched and less widely understood than for a CEA [9].
For instance, a previous review appears to classify nearly
all (57/68) economic evaluations of rotavirus vaccination
as BIAs if they provide an estimate of the net costs of
vaccination as part of a CEA, despite these estimated
economic (and often discounted) costs being very different
from the true financial stream of costs that would be esti-
mated within a BIA [15].
The first BIA analytic framework was published in 1998
[16]. Since then, additional publications have offered
methodological guidance for BIAs [7, 10, 17–19], most
recently, the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) Task Force’s best-prac-
tice recommendations on conducting BIAs [18]. The recent
ISPOR guidelines, however, do not include a checklist that
summarises the methodological recommendations and
supports a critical appraisal of the quality of BIAs. Such
checklists are useful in ensuring the quality of research
outputs. For example, CEAs are often appraised using
Drummond’s checklist for assessing economic evaluations
[20] or the Consolidated Health Economic Evaluation
Reporting Standards checklist [21].
In this study, we develop a framework that incorporates
the latest ISPOR recommendations into a BIA quality
assessment checklist. This framework can be turned into a
scoring system to critically assess the quality of a BIA.
While there have been previous quality appraisal checklists
in this area [14, 22], none have been explicit about how to
use them to grade individual studies in particular inter-
vention areas.
As an illustrative example, we develop a scoring system
for vaccines. Newer vaccines are more costly than tradi-
tional childhood vaccines, representing increasingly large
investments [23]. Delivery costs can be as great as vaccine
costs, creating sustainability challenges over the long term
[24]. Although development assistance for vaccination has
increased over the last two decades, this is still a small
proportion of total health expenditures for vaccination in
LMICs [25]. In particular, for countries ineligible for
assistance through Gavi, the Vaccine Alliance or those
graduating out of Gavi support, the long-term budget
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implications from new vaccine adoptions are very impor-
tant to consider. In fact, government expenditure on vac-
cines in countries that have adopted new vaccines was
recently found to be on average double that of countries
that have not [3].
As CEAs are more common than BIAs, particularly in
LMICs [14], it would be helpful if they could be adapted to
provide budget impact information without requiring much
additional data or analysis. Such pragmatic adaptations
could be immediately useful to policy makers seeking to
fill the gap in stand-alone BIAs. This idea has been pro-
posed by others in relation to vaccine CEAs, based on how
population estimates are taken into account [26]. However,
to the best of our knowledge, the feasibility of such
adaptation has never been systematically assessed, and
there is no existing guidance on preparing CEAs with such
an objective in mind. We therefore also modify the BIA
checklist and scoring system for CEAs, to evaluate whe-
ther, and if so, the extent to which, a CEA can be used to
provide sufficient information for a BIA.
We first systematically review the literature to identify
existing economic evaluations in LMICs. To keep the
review manageable, we focus on rotavirus vaccination,
which is recommended by the World Health Organization
for all countries, particularly those with high rotavirus
gastroenteritis case-fatality risks [27]. Most of the esti-
mated 215,000 deaths in children under 5 years of age from
rotavirus gastroenteritis occur in LMICs [28], and while
there exist many studies demonstrating the cost effective-
ness of rotavirus vaccination [15, 29], it has seen only
partial uptake in LMICs. We then apply the checklists and
scoring systems to examine the extent to which existing
economic evaluations provide sufficient evidence about
budget impact to enable decision making, and identify key
areas where BIA and CEA reporting could be improved for
this purpose.
2 Methods
2.1 Search Strategy
We conducted a systematic literature review to identify
economic evaluations of rotavirus vaccine in LMICs. Our
search was conducted in November 2015 and updated in
February 2017. We included articles published between
January 2000 and February 2017. Search terms were bro-
ken down into four components, which included terms
relating to (1) costs/BIA/CEA/economic evaluation, (2)
vaccines, (3) rotavirus and (4) LMICs [see Online
Resource 1 of the Electronic Supplementary Material
(ESM) for full details on search terms used].
Relevant Medical Subject Headings terms were included
where appropriate. We developed and used an LMIC filter
based on the most recent World Bank country income
classification [30], expanded to include 25 countries that
transitioned from low or middle income to high income
from 2000 to 2017. We supplemented our LMIC filter with
the Cochrane 2012 LMIC Filters [31] (Online Resource 2
of the ESM).
We searched the following electronic databases: Econ-
Lit, EMBASE (Ovid), MEDLINE (Ovid) and the National
Health Service Economic Evaluation Database (through
the Cochrane Library). Additionally, we ran basic searches
in Research Papers in Economics and the Tufts CEA
Registry [32]. We also carried out searches of the first 150
hits in Google and Google Scholar using BIA-specific
search terms to identify any unpublished BIAs (Online
Resource 1 of the ESM). We supplemented the database
searches by conducting manual bibliographic searches
from recent and relevant rotavirus vaccine review papers
[14, 15, 29, 33–35].
Duplicate citations were removed and all remaining
papers were screened based on title and abstract. Two
reviewers (NC and SC) screened titles and abstracts during
the original search conducted in November 2015. One
reviewer (NC) screened titles and abstracts identified in the
updated search conducted in February 2017. We verified
inclusion as a LMIC based on the World Bank’s fiscal year
at the time of publication. Two reviewers (NC and SC)
read the full text of papers identified as relevant. Non-
English language papers were translated to English. Studies
included consisted of those self-defined as a BIA or other
economic evaluation including a CEA and cost-utility
analysis (we refer to both types as CEA from now on).
Studies classified as a cost-benefit, fiscal or revenue anal-
ysis, or costing studies that did not capture both the costs of
rotavirus vaccination and the cost savings owing to reduced
disease, were excluded, as were papers tagged as Review,
Editorial, Perspective or Discussion pieces. Full inclusion
and exclusion criteria are summarised in Table 1. We
followed the Preferred Reporting Items for Systematic
Reviews and Meta-analysis guidelines and a checklist for
the review [36].
2.2 Development of a Budget Impact Analysis (BIA)
Checklist
Based on the ISPOR best-practice recommendations [18],
we produced a framework to provide guidance on assessing
the quality of BIAs. The BIA Checklist consisted of 15
items divided into four categories: Background, Interven-
tions, Analytic Framework and Results (Table 2). From this
framework, we developed a vaccine-specific scoring sys-
tem to critically appraise papers. Each item was assigned a
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full (1), partial (0.5) or null (0) score, based on how closely
the article met the relevant recommendation. Strict scoring
rules were followed for each item, as specified in Online
Resource 3 of the ESM, and described in the following
sections.
2.2.1 Background
For this category, relevant features of the healthcare system
that may influence the budget must be considered. We
identified five such features: financing available, budget for
vaccines, the country’s decision to introduce the new
vaccine, rotavirus disease burden and other relevant
healthcare system factors such as availability of infras-
tructure. The recommended perspective is that of the
decision maker or budget holder. Finally, the size of the
eligible population must be described and data sources or
approaches used to estimate population size explained.
2.2.2 Interventions
Articles should describe the current mix of interventions
and the expected mix after the introduction of the new
vaccine. This includes identifying all cost categories rele-
vant to the current mix of interventions, including outpa-
tient cases and hospitalisation. To receive a full score, we
specified that costs must be estimated using microcosting.
For pragmatic reasons, a study that uses local reimburse-
ment rates (or reference costs) from the country (for
example, based on a basic benefits package) was consid-
ered equivalent to microcosting. Second, the anticipated
uptake and coverage of the new vaccine must be consid-
ered. For a full score, the article must discuss where cov-
erage estimates come from, why they are reasonable, and
their reason for modelling or not modelling scale-up. Third,
all cost categories included in estimating the cost of vac-
cine introduction should be identified. This includes
microcosting of operational delivery and administration
costs of the vaccination programme in addition to speci-
fying the vaccine procurement cost. Finally, the impact on
healthcare costs should be modelled, including a descrip-
tion of how this was done.
2.2.3 Analytic Framework
Within this category, we assessed aspects related to mod-
elling choices and data inputs, including stating and justi-
fying a time horizon appropriate to the budget holder, not
discounting costs, and providing full details of the model
used and input parameters. If an article makes no mention
of discounting costs, we assumed no discounting was used.
We generated a list of the six most relevant data inputs:
demography; estimated vaccine coverage; burden of dis-
ease; vaccine efficacy; vaccine-related costs; and other
health systems-related costs. Articles were scored based on
how much local level data were used to inform these
inputs.
Table 1 Study inclusion and exclusion criteria
Include Exclude
Publisheda from January 2000 to February 2017 Publisheda before 2000
Focused on one or more LMICb Focused on high-income country(ies)
Target population children under 5 years of age Target population children over 5 years of age or unspecified
Intervention is any rotavirus vaccine delivered in any
manner
N/A
Full-text paper Abstracts, posters or presentations
1. Study self-described as a BIA
2. Other full economic evaluation (CEA or CUA)
1. Fiscal, revenue or cost-benefit analyses, or costing studies that do not capture
both:
(a) Costs of rotavirus vaccination; and
(b) Cost savings
2. Studies that do not report either:
(a) Novel analysis from primary data collection; or
(b) Secondary analysis or modelling of primary data
3. Review, editorial, perspective or discussion pieces
BIA budget impact analysis, CEA cost-effectiveness analysis, CUA cost-utility analysis, LMIC low- and middle-income country, N/A not
applicable
a If unpublished, refers to date reported
b Based on World Bank Analytical Classification using gross national income per capita (Atlas methodology), based on the World Bank’s fiscal
year at the time of publication
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Table 2 Items included in the budget impact analysis (BIA) checklist and modified BIA checklist for cost-effectiveness analysis
Item
no.
Category/itema Recommendation summaryb Classification for modified BIA checklist
for CEA
Background
1. Healthcare system/setting Consider relevant features of the healthcare system that may
influence budget and possible access restrictions
Desirable
2. Study perspective Perspective should be that of the decision maker/budget holder Essential
3. Eligible population Estimate size of eligible population, and distribution of any
characteristics that may influence budget impact
Essential: specify size of eligible
population
Desirable: describe characteristics/justify
population size estimates
Interventions
4. Current interventions Lay out the current mix of interventions (use and effects) and
the expected mix after the introduction of the new
intervention
Essential: health systems costs included
Desirable: microcosting of healthcare
systems costs
5. Uptake of new
intervention
Take into account the anticipated uptake of the new
intervention
Essential: report coverage level of new
intervention
Desirable: discussion of where coverage
estimates come from
6. Costs of introducing new
intervention
Identify all cost categories included. Describe approaches used
to estimate costs of new intervention
Essential: all intervention cost categories
included
Desirable: microcosting of intervention
costs
7. Impact on healthcare
systems costs
A description of how the intervention’s impact on healthcare
costs was modelled should be included, including estimation
of indirect effects where relevant
Essential: model impact of intervention
Desirable: describe how intervention
impact was modelled
Analytic framework
8. Time horizon State and justify the time horizon(s) over which costs and
consequences are being evaluated. Time horizon should be
appropriate to the budget holder
Essential: time horizon stated
Desirable: time horizon justified
9. Discounting and time
dependencies
Financial streams at each budget period should be
undiscounted. Other aspects that vary over time (inflation/
deflation, changes in price) should be included
Essential
10. Model type Describe and justify the specific type of model used Essential: report model used
Desirable: describe model used
11. Data sources Specify data sources and, if possible, obtain estimates directly
from budget holders
Desirable
Results
12. Cost estimates/budget
impact
Present results (both resource use and costs) for each budget
period after the new intervention is adopted
Essential
13. Validity Determine face validity through: (1) agreement with relevant
decision makers on the computing framework, aspects
included, and how they are addressed; and (2) verification of
cost calculator or model implementation, including all
formulas
Desirable
14. Uncertainty and scenario
analyses
Present alternative scenarios (e.g. allow users to view results
with and without condition-related costs, to include or
exclude different categories of costs)
Desirable
15. Conclusions and
limitations
State main conclusions on the basis of the results of the BIA.
Report the main limitations regarding key issues including
assumptions and completeness and quality of data inputs and
sources
Desirable
CEA cost-effectiveness analysis
a Each item gets a maximum score of 1 and a minimum score of 0. Items subdivided into ‘Essential’ and ‘Desirable’ components are scored 0/0.5
for each sub-component such that the maximum still sums to 1 for each item. Maximum score for the full checklist is 15 points. Maximum score
for Essential vs. Desirable items in the modified BIA checklist for CEA are six and nine points, respectively
b Adapted from Sullivan et al. (2014) (International Society for Pharmacoeconomics and Outcomes Research Task Force on Good Research
Practices—Budget Impact Analysis)
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2.2.4 Results
Results must be presented as estimates of financial costs at
each budget period after the new vaccine was introduced.
This final category also assessed the determination of face
validity, the presence of uncertainty and scenario analyses,
and the article’s main conclusions from a budget impact
perspective, including discussion of the main limitations.
For these last three sub-sections within the results (validity,
uncertainty and scenario analyses, and conclusions), scores
do not take into account how well each of these items was
done, but rather provides guidance on whether they were
done at all.
2.3 Development of a Modified BIA Checklist
for Cost-Effectiveness Analyses (CEAs)
We modified the BIA Checklist for CEAs by classifying
each item as ‘Essential’ or ‘Desirable’ for estimating
budget impact. Some items were subdivided into both an
‘Essential’ and ‘Desirable’ component. As a result, the
Modified BIA Checklist for CEAs consisted of ten Essential
components, and a further 12 Desirable components
(Table 2). The scoring system was similarly modified to
provide a ‘feasibility score’ to reflect a CEA’s suitability
for adaptation for BIA purposes (Online Resource 4 of the
ESM). Cost-Effectiveness Analyses were first scored on the
Essential criteria, and only articles receiving a full score
(6.5 points total) were assessed on the Desirable compo-
nents (8.5 additional points).
All articles included in the final review were scored
based on the BIA Checklist or the Modified BIA Checklist
for CEA scoring systems. The maximum score for both
checklists was 15 points. Two reviewers (NC and SC)
scored the articles independently. Scoring disagreements
across any of the items within the checklists were identified
and discussed by the two reviewers prior to jointly agreeing
on a score. If an agreement was not reached, the conflicting
scores were discussed with the broader team (all authors)
until a consensus was reached.
3 Results
3.1 Articles Included in the Review
Our search yielded 834 articles, of which 305 were dupli-
cates. The 529 original articles were screened for inclusion
and exclusion criteria based on title and abstract. Two
reviewers read the full-text version of 103 studies, of which
an additional 37 articles were excluded. Sixty-six articles
were included in the final review, of which six were BIAs
and 60 were CEAs (Fig. 1).
The six BIAs were published between 2010 and 2013,
and focused on countries across different regions of the
world (Indonesia, Thailand, Armenia, Brazil), with one that
evaluated rotavirus vaccine across all Gavi-eligible coun-
tries (Online Resource 5 of the ESM). Five BIAs were
conducted alongside a CEA.
The CEAs (Online Resource 5 of the ESM) were pub-
lished between 2005 and 2016, with the largest numbers of
studies published in 2009 and 2015 (12 in each year). The
CEAs focused on individual LMICs around the world as
well as groups of countries.
3.2 Assessment of Papers Reviewed
3.2.1 Application of the BIA Checklist
3.2.1.1 Background All BIAs described the burden of
rotavirus disease and whether a decision had been made to
introduce the vaccine in the country. Most (4/6) [37–40]
adequately described with justification the estimated target
population. All analyses were conducted from the decision
maker or budget holder’s perspective. Most BIAs fully
considered the relevant features of the healthcare system
that could influence the budget, and reported on the current
budget for existing vaccines as well as financing available
for the introduction of the new vaccine, such as whether the
country is eligible for Gavi support and, if so, when this
support would end.
3.2.1.2 Interventions All but one [40] BIA laid out the
current mix of interventions and expected mix after the
introduction of the new vaccine. Half [38–40] took into
account the anticipated uptake of the new vaccine,
including describing the estimated scale-up of the vaccine
over time with justification based on prior vaccine scale-up
trends or other sources. Most (4/6) BIAs [37–40] identified
all relevant cost categories and described the approaches
used to estimate the costs of introducing the new vaccine.
Some articles were penalised for not microcosting to esti-
mate costs associated with the current interventions (1/6)
[40] or the new vaccine (2/6) [41, 42], or not justifying the
coverage level at which the vaccine would be rolled out or
discussing scaling up (3/6) [37, 41, 42]. All BIAs modelled
the impact of the vaccine on health care costs and descri-
bed how this was done.
3.2.1.3 Analytic Framework All BIAs specified either
the programmatic time horizon or stated that they were
modelling one birth cohort; however, only two justified this
time horizon from the perspective of the budget holder
[38, 39]. All BIAs accounted for time dependencies of
costs; however, three discounted future costs at 3%
[37, 41, 42]. All articles described the model and input
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parameters, and used budget holder or local country-
specific data sources to inform model input parameters.
3.2.1.4 Results Only two BIAs presented financial cost
estimates and resource use at each budget period after the
new vaccine is introduced [39, 40]. One BIA presented
financial cost estimates only [38]; the remaining appeared
to present annual total costs based on a mature pro-
gramme operating at full scale [37, 41, 42]. Determina-
tion of face validity was present in some capacity in four
of six articles: one conducted a partial verification of
model projections by comparing two different models
[40]; three compared the financial cost estimates for one
budget period to the current immunisation budget in the
country [37, 41, 42]. With one exception [39], all BIAs
carried out uncertainty and scenario analyses. All but one
stated the main conclusions from a budget impact per-
spective [38], including discussion of the main
limitations.
Fig. 1 Literature search flow diagram. BIAs budget impact analyses, CEAs cost-effectiveness analyses, NHS EED RePEc. aIncluding one article
in Russian for which full text was sought but could not be obtained and one PhD dissertation thesis under embargo until 2018
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3.2.1.5 Overall BIA Quality Assessment Scores Among
all BIAs, validity, time dependencies and discounting, and
programmatic time horizon received the lowest average
scores across all checklist items. Average scores for the
BIA papers across each of the 15 checklist items are shown
in Fig. 2. Overall, the total score received by BIAs ranged
from 10.5 to 13.5 (out of a maximum of 15 points). Article-
specific scores for each checklist item are shown in Online
Resource 5 of the ESM.
3.2.2 Application of the Modified BIA Checklist for CEA
3.2.2.1 Background The majority of CEAs reviewed (53/
60) were conducted from the perspective of the decision
maker or budget holder. Many (38/54) also included some
form of a societal perspective. Of the seven CEAs not
conducted from the healthcare payer or provider perspec-
tive, most included household out-of-pocket costs that
could not be separated from the healthcare systems costs.
The size of the eligible population was specified or data
sources provided in most (53/60) CEAs.
3.2.2.2 Interventions All CEAs performed well in this
category. All articles received a full score for laying out the
current mix of interventions and expected mix after the
introduction of the new vaccine, taking into account the
anticipated uptake of the new vaccine, and modelling the
impact on healthcare costs. Most (56/60) CEAs adequately
identified all major cost categories relevant to the new
vaccine introduction.
3.2.2.3 Analytic Framework The programmatic time
horizon was clear in all but one CEA. All reported on the
model used for the analysis. In many cases (14/60), it was
unclear whether future costs were discounted or not. Either
nothing was stated or discounting was only mentioned in
the context of disease burden. The majority of articles that
discounted costs used a 3% discount rate. Less than half of
all studies (18/60) presented costs undiscounted or pre-
sented both discounted and undiscounted costs. While
some studies also specified varying the discount rate in
sensitivity analyses (usually assuming no discounting as a
lower bound), most did not adequately show their results
(total costs, or programme costs plus cost savings)
undiscounted.
3.2.2.4 Results The cost estimates/budget impact cate-
gory scored lowest of all items included in the modified
checklist. Only four of 60 CEAs received a full score,
while five articles received a partial score. Most articles
presented the total costs and/or resource use for the entire
period modelled, rather than disaggregating it year by year.
Furthermore, most articles did not present the true time-
varying financial costs of rolling out the vaccine and sub-
sequently scaling up incrementally, instead choosing to
report annualised costs based on a mature programme
operating at full scale.
3.2.2.5 Overall BIA Feasibility Scores for CEAs Average
BIA feasibility scores across all articles for the nine
essential items are shown in Fig. 3. The two worst per-
forming categories were ‘Discounting and time depen-
dencies’, and ‘Cost estimates/budget impact’. Overall
feasibility scores across all essential items ranged from 3 to
6.5, with an average of 4.7 out of 6.5 possible points. Three
papers scored full points (6.5/6.5) on the essential items
and were subsequently scored on the desirable items. Final
scores for the complete checklist ranged from 12 to 13.5
out of 15 possible points for these three CEAs (Online
Resource 5 of the ESM).
4 Discussion
The majority of economic evaluations of rotavirus vaccine
in LMICs identified in this review were CEAs. Only six of
66 articles were classified as a BIA, and all but one were
conducted alongside a CEA. The BIAs adhered well to the
majority of ISPOR’s best-practice recommendations.
However, our review identified three areas where BIAs fell
short from current best-practice recommendations: not
discounting future costs, providing annual or budget rele-
vant financial streams of costs and model validation. Most
BIAs were conducted alongside a CEA, and intervention
costs were often handled in a manner more appropriate to
CEA rather than BIA in terms of discounting and reporting.
Previous reviews of BIAs have determined that good
methods are not used consistently, with discounting,
reporting and sensitivity analyses also reported as key
issues in need of improvement, among others
[14, 19, 43, 44].
The majority of existing rotavirus CEAs did not provide
adequate detail to be useful for budget impact assessment.
Only three of 60 CEAs passed the ‘minimum requirements’
to be assessed using the full checklist. Similar to the BIAs,
CEAs rarely present undiscounted annual costs, or estimate
financial streams during the first few years of programme
scale-up. One pragmatic recommendation for CEAs (and
those who commission them) could therefore be to
explicitly require the reporting of yearly undiscounted
costs in addition to the standard reporting of costs within a
CEA (possibly in an appendix if not directly relevant for
the cost-effectiveness results), and estimates of real finan-
cial streams during the first few years of programme scale-
up.
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There are important limitations of this study that merit
mentioning. First, in constructing a checklist and scoring
criteria, we have simplified the recommendations laid out
by the ISPOR Task Force. While we attempted to capture
the most important considerations addressed in the best-
practice recommendations, the categories included in the
checklist are not an exhaustive list. For example, our
checklist does not capture whether the model allows users
to input or vary parameter values, an important consider-
ation for BIAs according to the guidelines. Additionally,
some categories included in the checklist can be subjective,
for example, stating appropriate conclusions and limita-
tions from a budgetary perspective. As such, in developing
the scoring system, we do not consider the quality and
completeness of each of the items in the checklist. Instead,
we have developed the scoring system to be as explicit as
possible for scoring vaccine-specific articles.
We focused only on full economic evaluations in this
review. Thus, we do not include vaccine costing studies
that may have tried to provide an estimate of budget impact
but did not take into account cost savings from reduced
burden on the healthcare system. Only a small number of
BIAs was included in our review, limiting the discrimi-
natory power of our checklist and the generalisability of
our findings to BIAs conducted in areas outside of rotavirus
vaccine. Finally, it is important to reiterate that the
majority of papers reviewed were not intended to be formal
BIAs. As such, the ‘feasibility’ scores for CEAs do not
reflect an assessment of their quality as an economic
evaluation per se, but rather the extent to which they pro-
vide useful budget impact information. This is especially
the case for articles scored only on Essential items. For
these items in particular, scores do not reflect how well, or
how appropriate for the budget holder this item was han-
dled in the analysis. Rather, they reflect whether or not the
item was taken into account or specified at all. For exam-
ple, CEAs specifying the size of the eligible population
score full marks for the essential component of this item,
regardless of whether the population size was appropriate
or justified.
Despite these limitations, our study provides a simple
and easily implementable quality assessment checklist and
illustrates how it can be converted into a scoring system, in
this case for vaccine-specific BIAs. It is to the best of our
Fig. 2 Average budget impact analysis checklist scoring for budget
impact analysis papers (n = 6). Average score (range in brackets)
shown for each category. Average overall quality score for all budget
impact analysis papers reviewed: 11.9 (10.5, 13.5) out of 15 possible
points. Each category is worth 0, 0.5 or 1 point (maximum = 1)
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knowledge, the first framework for systematically evalu-
ating the feasibility of adapting a CEA to a BIA. We
identified several areas where existing BIAs fell short from
best-practice recommendations. We also identified rela-
tively straightforward changes to the presentation of CEA
results that could facilitate the adaptation of most cost-
effectiveness studies into BIAs, potentially increasing their
utility and application. Although we have used produced a
vaccine-specific scoring system, the checklist could simi-
larly be adapted to other types of interventions.
To assist countries in making informed decisions about
adding a vaccine to a national immunisation programme,
the World Health Organization emphasises that program-
matic, economic and financial feasibility are important
criteria among others to consider [45]. This is especially
true in the case of LMICs not eligible for financial support
or price negotiations through Gavi and those graduating out
of Gavi support [4]. For these countries, the real fiscal costs
of introducing and sustaining new vaccines within immu-
nisation schedules will have enormous implications on a
country’s immunisation budget and overall healthcare
budget. The World Health Organization’s global vaccine
and immunisation policy recommendations also acknowl-
edge budget impact considerations as being highly relevant
alongside cost effectiveness [46].
There is potential for improved decision making in the
area of vaccines through programmes such as the ProVac
Initiative, which provides economic evaluation tools
including a CEA model (TRIVAC) and BIA model
(COSTVAC) along with country-level support. [47].
Beyond vaccines, the ‘Gates Reference Case, recently
developed through funding by the Bill and Melinda Gates
Foundation with the aim to improve the quality of eco-
nomic evaluations conducted in LMICs, recommends
reporting on budget impact as one of 11 key principles
[48].
The limited number of published rotavirus vaccine BIAs
in LMIC settings compared with CEAs may reflect the
need for more guidance on best-practice methodologies for
BIAs of preventive interventions in these settings. In the
context of the current difficulties in determining appropri-
ate threshold values for cost-effectiveness ratios in LMICs,
there is potentially greater value for budget impact esti-
mates for reflecting opportunity costs for these countries.
Additional use and validation of the BIA quality assess-
ment framework proposed in this review is necessary and
would be useful for further work. For example, these
checklists and a vaccine-specific scoring system could be
applied to economic evaluations of other vaccines, and
results compared with the findings in this review. Further
research is needed to investigate how this framework could
be adapted to other public health or medical interventions.
Fig. 3 Average modified checklist scoring for cost-effectiveness
analysis papers (n = 60). Average score (range in brackets) shown for
each ‘Essential’ category. Average overall feasibility score for all
cost-effectiveness analysis papers reviewed: 4.7 (3, 6.5) out of 6.5
possible points. Each category with a solid line is worth 0, 0.5 or 1
point (maximum = 1). Each starred category with a dashed line is
worth 0 or 0.5 points (maximum = 0.5)
88 N. Carvalho et al.
5 Conclusion
Both budget impact and cost effectiveness are key criteria,
among others, for policy makers deciding how to allocate
limited resources. In our study, we propose and demon-
strate the use of a generalised BIA checklist and vaccine-
specific scoring system for guiding and assessing the
quality of BIA as a stand-alone analysis or alongside CEA,
and highlight current gaps in standard practices. The pro-
posed framework could facilitate the uptake and improve-
ment of the quality of BIAs useful for decision making, in
particular in LMICs.
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